Novartis

Novartis licenses leukemia drug nilotinib to UN-backed Medicines Patent Pool

by

mizoula The United Nations-backed Medicines Patent Pool (MPP) said it sign a voluntary licensing agreement with Novartis (NYSE:NVS) to increase access to chronic myeloid leukemia (CML) drug nilotinib, sold as Tasigna. The plan to license the drug was reported earlier this year in May. The MPP said this was the first ever public health-oriented voluntary … Read more

Novartis Looks Appealing, Based on Drug Pipeline and Planned Spinoff

by

Text size These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or recommendations of Barron’s. Some of the reports’ issuers have provided, or hope to provide, investment-banking or other services to the companies being … Read more

Novartis to spin off generic drugs unit Sandoz

by

Pharmaceuticals company Novartis plans to spin off its generic drugs unit to form a publicly traded business, bringing to a close a restructuring that had drawn private equity suitors and calls for nationalisation. The Swiss group said the move to make Sandoz a separate entity would create the biggest generic drugs company in Europe by … Read more